FDA Approves Marketing Authorization Application for FGFR Inhibitor Futibatinib in Cholangiocarcinoma
ADC评论
October 3, 2022
On October 1, Taiho Oncology announced that the FDA has approved the marketing authorization application for the FGFR inhibitor futibatinib for the treatment of patients
